Short-, mid- and long-term efficacy of dupilumab in moderate to severe atopic dermatitis: a real life multicenter Italian study on 2576 patients.
Silvia FerrucciSimona TavecchioCarlo Alberto MaroneseAnna BalatoEugenia Di BrizziMichela OrtoncelliSimone RiberoGiampiero GirolomoniMartina MaurelliAnna Belloni FortinaFrancesca CaroppoLuigi NaldiElena PezzoloEustachio NettisFrancesco PuglieseLuca StingeniKatharina HanselGiovanni RubegniLaura CalabreseFilomena RussoMassimo GolaElisabetta MagnaterraFranco RongiolettiSanto Raffaele MercuriGiovanni PaolinoPaola SavoiaFederica VeroneseCaterina FotiFrancesca AmbrogioMassimiliano ScalvenziMaddalena NapolitanoCataldo PatrunoStefano DastoliMonica CorazzaAlessandro BorghiPier Giacomo Calzavara-PintonMariateresa RossiAnnamaria OffidaniGiulia RadiLaura BonzanoCaterina FerreliViviana PirasRosanna SattaFederica SucatoPiergiorgio MalagoliFrancesca GaianiGiuseppe MicaliMaria Letizia MusumeciMaria Concetta FargnoliMaria EspositoTeresa GriecoCamilla ChelloGiovanni CasazzaAngelo MarzanoPublished in: Clinical and experimental dermatology (2024)
High long-term effectiveness and safety of dupilumab were confirmed in this dynamic cohort of patients with moderate to severe AD, regardless of clinical phenotype and course at baseline. Further research will be needed to investigate the effect of Th2 comorbidities and disease duration on the response to dupilumab and other newer therapeutics for AD.